VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 that cover its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company's BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. This conditional activation mechanism aims to reduce off-target effects and enhance therapeutic windows, addressing key challenges in oncology drug development. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines.
The expanded patent portfolio reinforces VERAXA's long-term strategy to develop next-generation oncology therapeutics. The protection of core technologies through 2047 provides a competitive advantage in the rapidly evolving cancer therapy landscape, potentially impacting the development of more precise and safer treatments for patients. For the industry, this intellectual property strength may influence partnerships and licensing opportunities, as well as shape the direction of bispecific antibody and ADC research.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development.
For investors, the strengthening of VERAXA's patent estate underscores the company's commitment to protecting its technological innovations and could enhance its valuation and attractiveness for future collaborations. The news also signals the company's progress in building a robust pipeline that may address significant unmet medical needs in oncology. More information is available in the company’s newsroom at http://ibn.fm/VRXA.
The full press release can be viewed at https://ibn.fm/BqhFS. BiTAC is a registered trademark of VERAXA Biotech GmbH.
